UNITED KINGDOM – Merk & Co’s checkpoint inhibitor Keytruda, which has been available for three years through the Cancer Drugs Fund (CDF), has now been approved for routine NHS use…
Read MoreTag: Bristol-Myers Squibb
Sanofi inks megadeal with AI firm Exscientia to develop up to 15 new drugs
FRANCE – In a deal worth up to US$5.2 billion in milestone payments, French drugmaker Sanofi will collaborate with British AI firm Exscientia Plc to develop up to 15 drug…
Read MoreMerck has bagged another early cancer nod for Keytruda with FDA approval in post-surgery kidney cancer
USA – US Food and Drug Administration (USFDA) has approved Merck & Co.’s immunotherapy Keytruda for use in early kidney cancer, making it the first treatment of its kind available…
Read MoreAI giant Exscientia files IPO, raises over US$460 million for drug research and development
UNITED KINGDOM – Exscientia’s initial public offering and private placement has raised US$464 million to fund its artificial intelligence-based approach to drug discovery and development. The new cash infusion follows…
Read More